Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll o...
Find MoreThe prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to re...
Find MoreNon-alcoholic steatohepatitis (NASH) has emerged as a global health concern, affecting millions of individuals worldwide. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often resulting from the accumulation of fat in the liver. According to DelveInsight’s evaluation in 2022...
Find MoreNon-alcoholic fatty liver disease is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small number of NAFLD patients possess NASH. It is estimated that about 24% of U.S. adults have NAFLD, among which around 20%-...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.